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HIGHLIGHTS 
 CPET is a useful tool to stratify cardiovascular death risk in rec-HFmrEF population 
 Peak VO2 is the strongest independent predictor of cardiovascular death in rec-HFmrEF  
 Most of the CPET variables are associated to the cardiovascular risk in rec-HFmrEF  
 VO2 ≤ 55% and VE/VCO2 ≥ 31 identify the rec-HFmrEF subgroup at the highest risk 
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ABSTRACT 
Background–Heart failure with midrange ejection fraction (HFmrEF) represents a heterogeneous category 
where phenotype, as well as prognostic assessment, remains still debated. The present study explores a 
specific HFmrEF subset, namely those who recovered from a reduced EF (rec-HFmrEF) and, particularly, it 
focuses on the possible additive prognostic role of cardiopulmonary exercise testing (CPET). 
Methods and Results–We analyzed data of 4,535 HF with reduced EF (HFrEF) and 1,176 rec-HFmrEF 
outpatients from the Metabolic Exercise combined with Cardiac and Kidney Indexes (MECKI) database. The 
end-point was cardiovascular death at 5 years. The median follow-up was 1,343 days (25th–75th range, 
627-2,403 days). Cardiovascular death occurred in 552 HFrEF and 61 rec-HFmrEF patients. The multivariate 
analysis confirmed an independent role of the MECKI score’s variables in HFrEF (C-index=0.744) whereas, in 
the rec-HFmrEF group, only age and peak oxygen uptake (pVO2) remained associated to the end-point (C-
index=0.745). A pVO2 ≤55% of predicted and a ventilatory efficiency ≥31 resulted as the most accurate cut-
off values in the outcome prediction. 
Conclusions–Present data support the CPET and, particularly, the pVO2, as a useful tool in the rec-HFmrEF 
prognostic assessment. Peak VO2≤55% predicted and ventilatory efficiency ≥31 might help to identify a high 
risk rec-HFmrEF subgroup.  
 
 
Key-words: Heart failure; cardiopulmonary exercise test; prognosis; MECKI score. 
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INTRODUCTION 
The heart failure with midrange ejection fraction (HFmrEF) has been introduced originally in the 
2016 European Society of Cardiology (ESC) HF Guidelines and defined as a specific setting of HF 
characterized by an EF ranging between 40% and 49% (1). Differently from the well-known HF with reduced 
EF (HFrEF), conclusive data about the HFmrEF clinical profile are still lacking due to its relatively recent 
introduction and, most likely, its heterogeneous composition. Accordingly, again underlining the inherent 
difficulties in the HFmrEF univocal assessment, significant differences in prognosis between those HFmrEF 
patients who did not ever experienced a EF lower than 40% and those who recovered from a previous 
evidence of reduced systolic function (rec-HFmrEF) have been reported (2). 
The cardiopulmonary exercise test (CPET) pivotal role in the HFrEF clinical management either as a 
single CPET parameter (i.e. peak oxygen uptake, pVO2) (3), as a combination of CPET parameters (i.e. VO2 at 
the anaerobic threshold and ventilatory efficiency) (4), or as a part of more comprehensive scores (i.e. 
MECKI score, Metabolic Exercise combined with Cardiac and Kidney Indexes; HFSS, Heart Failure Survival 
Score) (5,6), is well established. Particularly, the MECKI score, including pVO2 and ventilatory efficiency 
together with four non-CPET prognostic variables (EF, haemoglobin, sodium, renal function), has been 
created (5), recently validated (7-9) and found, at present, as the most powerful outcome predictor at 1-2 
and 4 years of patients with HFrEF (9,10). Accordingly, it might reasonable that also in a multifaceted group, 
such as the HFmrEF population, the CPET might be extremely useful both to obtain a comprehensive 
functional and a prognostic assessment. Notwithstanding, up to now, just two studies, on relatively small 
and inhomogeneous populations, deal with a possible CPET role in the HFmrEF risk stratification (11-12). 
Therefore, aim of the present large Italian multicenter study was to characterize and to compare a 
large cohort of stable HFrEF and rec-HFmrEF patients on an optimized drug regimen both in terms of 
exercise capacity as well as of instrumental and laboratory variables. Thereafter a possible independent 
and incremental prognostic value of CPET parameters in identifying those rec-HFmrEF patients at high 
cardiovascular death risk has been explored.   
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METHODS 
- Study sample 
We retrospectively analyzed data of patients with HFrEF and rec-HFmrEF from the MECKI Score 
database which consists of 6,224 consecutive stable HF patients recruited and followed by MECKI Score 
Research Group in 27 Italian HF centres (5,10).  
All patients included into the MECKI Score database had HF signs and/or symptoms (NYHA 
functional class I to IV, stage C of American College of Cardiology/American Heart Association (ACC/AHA) 
classification) and were on stable clinical conditions with unchanged medications for at least three months. 
All patients had a former evidence of LVEF < 40% but all of them underwent an echocardiographic re-
evaluation before the CPET execution, thus allowing a re-categorization in HFrEF and rec-HFmrEF. Other 
primary inclusion criteria were no major cardiovascular treatment or intervention scheduled, and capability 
to perform a maximal, symptom-limited CPET. Conversely, the exclusion criteria were history of pulmonary 
embolism, primary valvular heart disease, pericardial disease, severe obstructive/restrictive lung disease, 
primary pulmonary hypertension, moderate to severe anemia (haemoglobin < 10 g/dl), significant 
peripheral vascular disease, and exercise-induced angina and/or ST changes. HF patients with second or 
higher degree atrio-ventricular block and those with a pacemaker-dependent heart rate were also 
excluded.  
The study and the access to personal health data were approved by local internal review boards, 
and all patients gave written informed consent to participate in the study.  
- Cardiopulmonary exercise testing  
A maximal, symptom-limited CPET was performed in 95% of the cases on an electronically braked 
cycloergometer connected to a metabolic chart. A personalized ramp exercise protocol was chosen, aiming 
at a test duration of 10±2 min (13). The exercise was preceded by a 2 minutes of resting breath-by-breath 
gas exchange monitoring and by a three-minute unloaded warm-up. A 12-lead electrocardiogram (ECG), 
blood pressure, and heart rate (HR) were also recorded. Specifically, baseline HR and peak HR were 
collected during CPETs, baseline HR being measured after at least 2 min of rest in a seated position on the 
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cycloergometer. In around 5% of the cases, CPETs were performed applying a modified Bruce protocol on a 
treadmill and in such a cases, peak VO2 values were reduced by 10% in order to compare functional data 
obtained from these two different exercise protocols. Peak HR was also analyzed as a % of maximum 
predicted value according to the standard formula (14). CPET was self-terminated by the subjects when 
they claimed that they had achieved maximal effort and as confirmed by a peak respiratory exchange ratio 
(RER) ≥ 1.05. A breath-by-breath analysis of O2, carbon dioxide (CO2) and ventilation (VE) was performed 
and peak values were computed as the highest observed measurements (20 s average). The predicted peak 
VO2 was determined by using the sex, age, and weight-adjusted Hansen/Wasserman equations (15).  
AT was identified through a V-slope analysis of VO2 and CO2 production (VCO2), and it was 
confirmed through the specific behaviour of the ventilatory equivalents of O2 (VE/VO2) and CO2 (VE/VCO2), 
as well as through the end-tidal pressure of O2 and CO2 (16) The relation between VE and VCO2 was 
analysed as the slope (VE/VCO2 slope) of the linear relationship between VE and VCO2 from one minute 
after the beginning of loaded exercise to the end of the isocapnic buffering period. Notably, all tests were 
re-evaluated by experts blinded to patients’ clinical features, and at least one of the local CPET experts 
underwent a training program at Centro Cardiologico Monzino. 
- Patients’ follow up and study end-point 
Patients’ prospective follow-up was carried out according to the local HF program. All HF centres 
participated in the MECKI Score research group, whose protocol was preliminarily established and reported 
(5). Briefly, follow-up started when clinical evaluation and CPET were performed, and it ended with the last 
clinical evaluation in the respective enrolling centre, or with the patient’s death or cardiac 
transplantation/left ventricular assistance device (LVAD) implantation. In the present analysis the selected 
study end-point was pure cardiovascular death, whereas patients who died from non-cardiac causes as well 
as those who underwent cardiac transplantation or LVAD implantation were considered as censored at the 
time of the event. 
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- Statistical analysis 
Unless otherwise indicated, all data are expressed as mean ± standard deviation (SD). Data with 
skewed distribution are given as median and interquartile range (75th percentile - 25th percentile). 
Categorical variables were compared with a difference between proportion test; a two-sample t-test was 
used to compare the general characteristics and other continuous linear data between the study groups; 
Wilcoxon test was used to compare non-normally distributed variables.  
We focused firstly on possible difference with respect the distribution of survival times at 5 years in 
the two study groups (HFrEF and rec-HFmrEF) by adopting the Cox proportional-hazards regression model. 
We performed a stepwise selection of the predictors to be included in the model as a mix between forward 
and backward selection. Given that we cannot include parameters with multicollinearity in the multivariate 
Cox analysis, pVO2 and VO2AT were added to the prognostic model one at a time. In order to determine 
whether a fitted Cox regression model adequately describes the data, we considered three kinds of 
diagnostics: (a) for violation of the assumption of proportional hazards; (b) for influential data; (c) for 
nonlinearity in the relationship between the log-hazard and the predictors. A test of the proportional 
hazards assumption was performed for each covariate by correlating the corresponding set of scaled 
Schoenfeld residuals with a transformation of time based on the Kaplan-Meier estimate of the survival 
function. Focusing on residuals, a graphical diagnostic can be provided to check for influential observations. 
A matrix of estimated changes in the regression coefficients was obtained upon deleting each observation 
in turn. Then, the magnitudes of the largest obtained values were compared to the regression coefficients. 
Given that an incorrectly specified functional form in the parametric part of the model (e.g. nonlinearity) 
might be a potential problem in Cox regression, the Martingale residuals were plotted against predictors to 
detect nonlinearity. Nonlinearity was obviously not an issue for dichotomous predictors.  
As a confirmation of the first survival analysis, to exclude a possible interference of a number of 
general parameters known to impact per se on HF prognosis, we performed 1:1 statistical matching 
between the two study groups according to the main clinical variables possibly acting ad confounders 
(nearest neighbor matching). Kaplan–Meier survival analysis was then repeated on a total of 1069 patients 
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per group matched for the following variables: age, gender, BMI, MDRD, NYHA class, Hb, Na and pVO2 (% of 
predicted), VE/VCO2 slope and disease modifier drugs (angiotensin converting enzyme 
inhibitors/angiotensin receptor antagonists, β-blockers and mineralocorticoid receptor antagonists).  
Finally, within the rec-HFmrEF group only, receiver-operating curves (ROC) were also estimated to 
display the capacity of pVO2 (% of predicted) and ventilatory efficiency (VE/VCO2 slope) to discriminate 
between survivors and non-survivors. According to this approach, we reported the thresholds 
corresponding to the best sum of sensitivity and specificity. Moreover, we tested the additive role of age on 
top of the pVO2 and VE/VCO2 slope to predict cardiovascular risk. To validate the CPET-derived parameters 
accuracy data, we introduce confidence intervals (CI) for all the considered quantities and all the CI of the 
sensitivity at the given specificity points (and viceversa) were computed based on 2,000 bootstrap 
replicates. A similar approach was adopted for the positive and negative predictive values.  
Statistical analysis was performed using R (R Development Core Team, 2009) packages. All tests 
were two-sided. A p value lower than or equal to 0.05 was considered as statistically significant. 
RESULTS 
Starting from 6,224 patients, a total of 5,711 met the inclusion/exclusion criteria and were 
considered for the present study. At the run-in, which included clinical, laboratory, instrumental 
assessment with echocardiographic and CPET execution, 4,535 patients had still a LVEF < 40% (HFrEF group) 
whereas the remaining 1,176 patients showed a LVEF between 40% and 49% (rec-HFmrEF group).  
- General characteristic of the study groups 
Table 1 reports a detailed comparison between the main clinical, echocardiographic, laboratory, 
CPET data as well as concomitant therapeutic strategies collected at the study run-in in the two study 
groups, namely the rec-HFmrEF and HFrEF. Echocardiographic and laboratory data (LVEF, pulmonary artery 
systolic pressure, Na+, BNP/NT-proBNP) were significantly better in the rec-HFmrEF group. Particularly, the 
rec-HFmrEF group was older with a higher prevalence of female gender, atrial fibrillation as well as a lower 
percentage of ischemic etiology (Figure 1, panel A). With respect the therapeutic strategy, angiotensin 
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converting enzyme inhibitors (ACEi)/angiotensin receptor antagonists (ARBs), β-blockers and 
mineralocorticoid receptor antagonists (MRA) were less represented in the rec-HFmrEF group than in the 
counterpart (Figure 1, panel B). Finally, as expected, the rec-HFmrEF group showed a less severe functional 
impairment in terms of all available CPET parameters (Figure 1, panel C).  
 
TABLE 1. Main clinical variables of the overall HF study sample according to LVEF category. 
 
 
General data 
rec-HFmrEF  
(n: 1,176) 
 
HFrEF 
(n: 4,535) 
P value 
Age, years 63±13 61±12 <0.001 
Male,n % 916 (78) 3848 (85) <0.001 
Body mass index, kg/m2 27±4 27±4 NS 
NYHA III, n (%) 
1  
2 
3 
 
250 (21) 
  731 (62) 
195 (17) 
 
600 (13) 
2433 (53) 
1502 (34) 
<0.001 
Ischemic etiology, n (%) 
 
412 (35) 
 
1936 (43) <0.001 
AF, n (%) 217 (19) 678 (15) 0.004 
Hemoglobin, g/dL 13.4±1.6 13.5±1.6 NS 
Sodium, mmol/L 139±3 138±3 0.015 
MDRD, ml/min/ 72 ±24 71±24 NS 
Rest HR, bpm 68±11 71±13 <0.001 
SBP, mm Hg 121±17 116±17 <0.001 
DBP, mm Hg 75±10 72±10 <0.001 
LVEF, % 44 ±3 28 ±7 <0.001 
PASP, mmHg  
NT-proBNP, pg/ml 
BNP pg/ml 
33 ±11 
443 [800] 
110 [210] 
38 ±13 
1002 [1842] 
377 [764] 
<0.001 
<0.001 
<0.001 
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ICD, n (%) 
CRT-D, n (%) 
167 (14) 
  71 (6) 
1736 (38) 
686 (15) 
<0.001 
<0.001 
Exercise test variables    
AT identified, n (%) 939 (80) 3691 (81) NS 
VO2 at AT, ml/min 891±318 783±284 <0.001 
VO2 at AT, ml/kg/min   11.4±3.8 10.1±3.2 <0.001 
pVO2, ml/min 1252±473 1111±401 <0.001 
pVO2, ml/kg/min 16.1±5.5 14.4±4.5 <0.001 
pVO2, % of predicted 63±18 53±16 <0.001 
VE/VCO2 slope 30.8±6.5 33.4±8.1 <0.001 
Peak HR, bpm 121±26 118±24 0.001 
pHR%, % of predicted 79±17 75±15 <0.001 
Peak workload, Watts 92±38 79±32 <0.001 
RER 1.13±0.6 1.11±0.07 NS 
Treatment    
ACEi or ARBs, n (%) 1081 (86) 4261 (93.2) 0.011 
Beta-blockers, n (%) 981 (83) 4048 (89.3) <0.001 
Beta-blockers dosage, mg 18.75 [12.50] 18.75 [12.5] 0.819 
MRA, n (%) 478 (40) 2624 (58) <0.001 
Loop diuretics, n (%) 822 (70) 3832 (84)   <0.001 
Digoxyn, n (%) 161 (14)   1027 (23) <0.001 
Amiodaron, n (%) 255 (22) 1241 (27) <0.001 
Data are expressed as mean ± SD, as absolute number of patients (% on total sample) or as median [25th-
75th percentile]. ACEi: angiotensin converting enzyme inhibitors; AF: atrial fibrillation; ARBs: angiotensin 
receptor blockers; AT: anaerobic threshold; BNP: b-type natriuretic peptide; CRT-D: cardiac 
resynchronization therapy implantable cardioverter defibrillator; DBP: diastolic blood pressure; HR: heart 
rate; ICD: implantable cardioverter defibrillator; LVEF: left ventricular ejection fraction; MDRD: Modification 
of Diet in Renal Disease; MRA: mineralocorticoid receptor antagonists; NT-proBNP: N-terminal pro b-type 
natriuretic peptide; NYHA: New York Heart Association; PASP: pulmonary artery systolic pressure; pHR: 
peak heart rate; RER: respiratory exchange ratio; SBP: systolic blood pressure; VE/VCO2: ventilatory 
equivalents of CO2; pVO2: peak oxygen consumption.  
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The median follow-up was 1343 days (25th–75th interquartile range,627 - 2403 days). Survival 
analysis showed a significantly better survival of the rec-HFmrEF group with respect the counterpart (p < 
0.0001) (Figure 2, panel A) being cardiovascular death occurred in 93 rec-HFmrEF patients (7.5%) and 754 
(16.6%) HFrEF patients with most of the cardiovascular death registered within the fifth years of follow up 
[61 patients (5.2% event rate) in the rec-HFmrEF group and 552 patients (12.2% event rate) in the HFrEF 
group]. A total of 255 patients died from non-cardiac-related causes, whereas 167 patients, mostly in the 
HFrEF, underwent heart transplantation or LVAD implantation.  
Table 2 reports the univariate analysis of the main significant clinical variables with respect the pre-
specified end-point at 5 years in the two study groups. Albeit with different magnitudes, most of the 
general, echocardiographic, laboratory  and CPET data were significantly associated to cardiovascular death 
in both groups (age, atrial fibrillation, LVEF, Hb, Na, MDRD, AT identification, VO2 at AT, pVO2 also expressed 
as percentage of the maximum predicted, VE/VCO2 slope) except for the lack of a protective role in the rec-
HFmrEF group of male gender, high BMI and preserved chronotropic response.  
         
13 
 
TABLE 2. Univariate Cox proportional survival analysis in the study groups according to the specified end-point (CV mortality at 5 years). 
 rec-HFmrEF (n. 1176)  HFrEF (n. 4535) 
 UNIVARIATE UNIVARIATE 
 H.R. (95% C.I.) P values C-index H.R. (95% C.I.) P values C-index 
Age 1.06 (1.04-1.082) <0.001 0.675 1.032 (1.026-1.039) <0.001 0.593 
Male  1.280 (0.765-2.142) NS -- 1.562 (1.242-1.965) <0.001 0.525 
Body mass index 0.950 (0.900-1.003) NS -- 0.963 (0.946-0.980) <0.001 0.563 
AF  1.937 (1.237-3.032) 0.004 0.562 1.579 (1.325-1.883) <0.001 0.539 
LVEF  1.081 (1.009-1.158) 0.027 0.578 0.938 (0.928-0.948) <0.001 0.629 
Haemoglobin 0.811 (0.715-0.920) 0.001 0.625 0.814 (0.776-0.855) <0.001 0.600 
Sodium 0.930 (0.877-0.986) 0.015 0.555 0.945 (0.926-0.965) <0.001 0.567 
MDRD 0.977 (0.967-0.987) <0.001 0.659 0.979 (0.975-0.982) <0.001 0.635 
AT identified 0.341 (0.158-0.738) 0.006 0.567 0.714 (0.552-0.810) 0.032 0.513 
VO2 at AT, ml/kg/min 0.915 (0.845-0.990) 0.028 0.589 0.871 (0.845-0.897) <0.001 0.624 
pVO2, ml/kg/min 0.872 (0.829-0.918) <0.001 0.675 0.859 (0.842-0.876) <0.001 0.671 
pVO2, % of predicted 0.964 (0.952-0.978) <0.001 0.687 0.959 (0.954-0.964) <0.001 0.679 
VE/VCO2 slope 1.061 (1.034-1.089) <0.001 0.661 1.056 (1.048-1.084) <0.001 0.660 
pHR%, % of predicted 1.010 (0.999-1.021) NS -- 0.990 (0.985-0.994) <0.001 0.549 
H.R.: hazard ratio; C.I. : confidence interval. See table 1 for other abbreviations
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By pursuing a multivariate approach via a multivariate Cox analysis, in the HFrEF group, besides the 
well-known six variables included in the MECKI score (LVEF, Hb, Na, MDRD, pVO2, VE/VCO2 slope), also age 
was independently associated to cardiovascular death (C-index for the entire model 0.744) (table 3). 
Conversely, in the rec-HFmrEF group, just two variables, namely age and pVO2 expressed as percentage of 
the maximum predicted, remained significantly associated to the outcome (C-index for the entire model 
0.745) (table 3). We also sought for possible interactions between treatment and the other independent 
variables, but the Akaike Information Criterion (AIC) (used to perform model selection) did not speak in 
favor of the inclusion of any interactions.  
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TABLE 3. Multivariate Cox proportional survival analysis in the study groups according to the specified end-point (CV mortality at 5ys). 
 rec-HFmrEF (n. 1176) HFrEF (n. 4535) 
 MULTIVARIATE MULTIVARIATE 
 H.R. (95% C.I.) P values  H.R. (95% C.I.) P values  
Age 1.044 (1.016-1.074) 0.001  1.021 (1.012-1.031) <0.001  
LVEF 1.082 (0.989-1.184) 0.084  0.957 (0.943-0.971) <0.001  
Haemoglobin 1.011 (0.852-1.198) 0.904  0.902 (0.846-0.958) <0.001  
Sodium 0.965 (0.905-1.030) 0.286  0.952 (0.927-0.978) <0.001  
MDRD 0.987 (0.974-1.001) 0.077  0.990 (0.985-0.994) <0.001  
pVO2, % of predicted 0.965 (0.947-0.983) <0.001  0.971 (0.963-0.978) <0.001  
VE/VCO2 slope 1.010 (0.973-1.048) 0.609  1.018 (1.001-1.030) 0.003  
   C-index for the model 
0.745 
  C-index for the model 
0.744 
H.R.: hazard ratio; C.I. : confidence interval. See table 1 for other abbreviations
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After the 1:1 matching the survival matched analysis confirmed the just observed favorable 
outcome of the rec-HFmrEF category with respect the HFrEF group (p < 0.0001) (Figure 2, panel B). Within 
the supplementary file, Table 1S shows a detailed comparison between these subgroups whereas Table 2S 
and Table 3S report the univariate and multivariate analysis data which substantially overlap with those 
obtained in the whole study groups.  
Finally, focusing on the rec-HFmrEF population, the ROC curve analysis showed that the best pVO2 
threshold, expressed as % of the maximum predicted, was equal to 55% (sensitivity 65%; specificity 62%; 
area under the curve (AUC) 69%) whereas the best VE/VCO2 slope cut-off value was 31 (sensitivity 56%; 
specificity 73%; area under the curve (AUC) 67%) (Figure 3, Panel A and B). By adopting both the 
abovementioned threshold values in order to identify a rec-HFmrEF patient at high risk of cardiovascular 
death, the model shows a sensitivity nearly to 80% with a positive predictive value of higher than 90% 
(table 4) (Figure 3, Panel C). Conversely, no advantage has been found in including the age into the model. 
Validation by bootstrap analysis confirmed the robustness of the abovementioned accuracy data (i.e. 
sensitivity/specificity and positive/negative predictive values). 
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Table 4. Accuracy of the main CPET variables in the rec-HFmrEF study sample according to the cut-off identified at ROC analysis. 
CPET variables R.R.  
(95% C.I.) 
P 
value 
Sensitivity, % 
(97.5% C.I.) 
Specificity, % 
(97.5% C.I.) 
PPV, % 
(97.5% C.I.) 
NPV, % 
(97.5% C.I.) 
A.U.C. 
pVO2 < 55% of predicted 3.1  
(1.825-5.321) 
<0.001 65.1 
(62.2-67.9)          
62.2 
(48.9-74.4) 
97.1 
(96.4-97.6) 
8.3 
(6.1-11.1) 
68.7 
(62.1-72.6) 
VE/VCO2 slope > 31 3.5  
(1.981-6.451) 
<0.001 56.5 
(53.4-59.4) 
72.8 
(59.7-83.6) 
96.9 
(96.4-97.4) 
9.8 
(6.7-14.3) 
67 
(59.9-74.1) 
pVO2 < 55% and VE/VCO2 slope > 31 3.8 
 (2.197-6.323) 
<0.001 78.8 
(76.3-81.2) 
 
50.0 
(36.8-63.2) 
96.9 
(95.9-97.6) 
10.6 
(8.4-13.2) 
--- 
R.R.: relative risk; C.I.: confidence interval; PPV: positive predictive value; NPV: negative predictive value. 
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DISCUSSION 
The present multicenter study supplied a comparison of several clinical variables between a large 
cohort of stable HFrEF and rec-HFmrEF outpatients on optimized drug regimen. Besides confirming the 
expected clinical, functional and outcome differences between groups as well as the pivotal prognostic role 
of CPET parameters in the HFrEF (3-5, 17-20), our data strongly supports a possible usefulness of CPET in 
the rec-HFmrEF management, too. Particularly, within this specific HFmrEF subset, both a reduced pVO2 
value and an impaired ventilatory efficiency (increased VE/VCO2 slope value) were significantly associated 
to a long term increased risk of cardiovascular death.  
Differently from HFrEF, the well-behaved “older sibling child”, whose clinical features and prognosis have 
been extensively described, few data are available on HFmrEF, the “middle child” unloved and neglected 
(21-25). Indeed, with respect a possible distinct phenotype, some previous studies reported that this HF 
category has a peculiar clinical profile between HFrEF and HF with preserved EF (HFpEF) (26-30). 
Particularly, compared to those with HFrEF, HFmrEF patients are usually older, more predominantly female 
and more likely affected by diabetes, atrial fibrillation and chronic kidney disease. Conversely, with respect 
the HFpEF, this category seems to suffer more frequently from ischaemic heart disease and, by a lesser 
extent, from hypertension and valvular disease (21). Similarly, even from a prognostic viewpoint, patients 
with HFmrEF have been reported to show an “intermediate” behavior between HFrEF and HFpEF patients 
(21,26,31). Eventually, differently from the “older sibling child”, it has been shown that HFmrEF patients are 
usually undertreated with the HF disease modifier drugs, namely angiotensin converting enzyme inhibitors 
(ACEi)/angiotensin receptor antagonists (ARBs), β-blockers and mineralocorticoid receptor antagonists 
(MRA) (32), most likely because of a not univocal pharmacological strategy in this new born HF setting. 
Adding further complexity to the HFmrEF clinical scenario, it is still debated whether the HFmrEF should be 
considered as a real clinical entity or just as a transition step of the dynamic functional and structural 
evolution of the continuous HF spectrum (24,33,34). However, another viewpoint, actually the prevalent 
one, distinguishes those HFmrEF patients who recovered from a depressed systolic function (rec-HFmrEF) 
from those who never experienced a EF lower than 40% (de novo HFmrEF). In such a context, Nadruz and 
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colleagues reported a lower risk of cardiovascular events in rec-HFmrEF than in HFrEF and, quite 
surprisingly, even lower than in de novo HFmrEF (2). Similar results have been achieved also in a large 
registry study by Park CS and colleagues where it has been shown a lower rate of all-cause mortality in the 
rec-HFmrEF subset (35). Due to the significant differences in the study design, such as the primary outcome 
(i.e. they explored a combined endpoint of all-cause mortality), as well as in the characteristic of the 
analyzed sample (i.e. they evaluated acutely decompensated patients), a comparison between our results 
and those presented by Park and colleagues cannot be feasible or, even, misleading (35). Conversely, with 
respect to the rec-HFmrEF population studied by Nadruz (2), besides the consistently larger cohort 
evaluated (1176 versus 170 patients), there are some aspects worthy to be discussed briefly. 
Notwithstanding, our sample tends to overlap for haemoglobin levels, renal function and EF, however it 
appears significantly older, with a higher prevalence of male sex, ischaemic heart disease and concomitant 
MRA treatment. Eventually, even if our survival analysis shows a lower incidence of events at 5-years (5.2% 
versus nearly 8%), it should be remarked that we explored pure cardiovascular death rate rather than the 
overall mortality analyzed in the other study.  
Nadruz and colleagues characterized their cohort from a functional viewpoint through a CPET 
assessment, however they did not investigate a possible association between the CPET-derived parameters 
and the outcome. Furthermore, due to the difference in the patients’ characteristics (i.e. they analyzed a 
younger cohort with a higher prevalence of female and a lower incidence of ischaemic heart disease than 
the one explored in the present study) it is difficult to compare our CPET data with those obtained in the 
rec-HFmrEF population analyzed by Nadruz (36). Conversely, two recent studies explored the prognostic 
power of CPET-derived parameters in HFmrEF, albeit in relatively small and inhomogeneous samples 
(11,12). Sato and colleagues found that pVO2 lower than the observed median values, within a cohort of 
254 HFmrEF patients, was the only independent predictor of cardiac and all-cause deaths (11). Compared 
to our HFmrEF sample, their cohort had a higher prevalence of ischemic heart disease, atrial fibrillation and 
renal insufficiency. In another study by Nadruz and colleagues, involving 144 HFmrEF patients, pVO2 
(expressed as ml/kg/min) and VE/VCO2 slope were associated with a composite outcome of all-cause death, 
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LVAD implantation and heart transplantation (12). It should be underlined that the patients enrolled by 
Nadruz and colleagues were younger and with a lower male and ischemic heart disease prevalence with 
respect those enrolled in our study. Unfortunately, given that any of the abovementioned studies analyzed 
a pure rec-HFmrEF setting, it remains difficult a strict comparison with respect clinical and survival data. In 
fact, the present study addressed specifically a possible advantage of CPET in a rec-HFmrEF cohort and it 
strongly supports the pVO2, expressed as % of the maximum predicted, as the unique instrumental 
parameter able to predict independently the cardiovascular death risk. Why just pVO2, but not other key 
clinical and instrumental variables (i.e. those included in the MECKI score), seems to better define the 
cardiovascular risk in such HF category might be due proper to its multidimensional character (37). Indeed, 
according to the Fick law, pVO2 represents the product between cardiac output and artero-venous O2 
difference, both factors being impaired, although with different extent, in rec-HFmrEF patients. Moreover, 
particularly due to the demographic characteristics, our data argue in favor of the pVO2 expressed as the 
percentage of the maximum predicted rather than just corrected for the body weight (15). Noteworthy, 
besides the pVO2, most of the CPET-derived variables were univariately associated to the pre-specified end-
point, including the VE/VCO2 slope, the VO2 at the AT as well as an AT not identified, each of them known 
powerful outcome predictor in the “older sibling child” HFrEF. In such a context, with respect to the Sato 
and Nadruz studies (11,12), we propose a possible easy approach to identify and, possibly, to treat more 
aggressively those rec-HFmrEF at higher cardiovascular death risk by means of both pVO2 and VE/VCO2 
slope cut-off values. Indeed, we identified a pVO2 <55% of predicted and a VE/VCO2 slope >31 as the most 
accurate cut-off values able to identify a rec-HFmrEF subgroup with a cardiovascular mortality rate 
significantly higher than the overall rec-HFmrEF (5.2% vs 8.5%). Furthermore, by using both cut-off values 
contextually, we were able to identify a relatively small rec-HFmrEF population with a cardiovascular risk 
quite similar to the HFrEF sample (12.2% vs 11.4%) and, contextually, a huge number of rec-HFmrEF 
patients a cardiovascular death risk lower than 2% (those with a pVO2 > 55% of predicted and a VE/VCO2 
slope < 31) (Figure 4). Of note, the lack of an additive prognostic role of age on top of the combined model 
might be due to the close relationship of this variable with both the pVO2, expressed as a percentage of its 
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predicted normal value and, albeit to a lesser extent, the VE/VCO2 slope (36). However, albeit easy to use 
in daily clinical practice, it should be underlined that it is undoubtedly more appropriate from a clinical and 
pathophysiological viewpoints to consider these two CPET parameters as continuous variables rather than 
categorical. Supporting the need of a reasoned and multidimensional rather than a CPET-centered 
approach, the accuracy of the model using only cut-off values, although validated by boot strapping 
analysis and characterized by high positive predictive values, remains suboptimal. Of note, our decision to 
include the ventilatory efficiency into our accuracy analysis, regardless not independently associated to the 
pre-specified end-point, is based not only on its well-established prognostic role both in HFrEF and HFpEF 
but mainly on another possible advantage. Indeed, the VE/VCO2 slope may represent a pivotal CPET 
parameter in those cases (i.e. elderly and highly comorbid HF patients) where it is difficult to achieve the 
metabolic criteria for consider a CPET as maximal (38). 
LIMITATIONS 
Albeit its retrospective feature, the present study has been conducted on a sizable cohort with a 
nearly four years median follow-up and all the centers involved were highly experienced with HF 
management and CPET analysis. However, a few limitations should be acknowledged.  
Firstly, we examined the prognostic impact of several variables at a single time point. Therefore, 
considering the long follow-up period, we cannot exclude that changes in some clinical strategies (i.e. 
upgrading of pharmacological treatment and/or, devices implantation) altered our survival analysis as well 
as a possible patients’ transition to another LVEF category. Secondly, it should be reasonable that the lack 
of significance of some variables at multivariate analysis in the rec-HFmrEF with respect the HFrEF group, 
albeit coefficients similar in direction and magnitude in the stratified univariate analysis, might be driven 
much more by the differences in sample size between groups than to the an effective lack of clinical 
relationship in the rec-HFmrEF group. Conversely, even if it could be considered a little bit more than a 
trend, in our rec-HFmrEF population a significantly higher LVEF has been found associated to a greater 
cardiovascular death risk. Of note, also this somewhat paradoxical relationship disappears at multivariable 
analysis casting doubts about its possible pathophysiological meaning. However, in such a case, a possible 
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highly speculative explanation might be that it was a consequence of a further less strict therapeutic 
strategy in those rec-HFmrEF with a better ventricular function. Thirdly, as previously discussed, we 
examined only rec-HFmrEF patients and this aspect could be, at the same time, a strengthen but also a 
weakness of the current study. Unfortunately, because all patients came from the MECKI score database, 
we were not able to include a comparison with a de novo HFmrEF as well as a HFpEF cohort. Moreover, 
again due to the design of the MECKI score dataset, the lack of data with respect the timeline between 
disease onset and LVEF recovery does not allow us to speculate about a possible impact of the medical 
treatment length on the HF category interchange. Last, the pre-specified study end-point was pure 
cardiovascular mortality prevented us from even speculating on possible different mode of death between 
rec-HFmrEF and HFrEF (i.e. sudden cardiac death or HF worsening) as well as possible specific attitude of 
the explored variables in identifying the mode of death. 
CONCLUSIONS 
In conclusion, the actual retrospective analysis of data coming from the large multicenter MECKI 
score dataset, besides confirming the independent role of some CPET, instrumental and laboratory 
variables in stratifying the cardiovascular risk in HFrEF, argues in favor of the adoption of this safe and 
noninvasive diagnostic approach in the rec-HFmrEF category clinical management, too. Even, besides the 
pVO2 which resulted independently associated, also a number of other CPET variables were univariately 
associated to the cardiovascular death risk. Particularly, a pVO2 ≤ 55% of the maximum as well as a VE/VCO2 
slope ≥ 31 identified a rec-HFmrEF subgroup of patients with a cardiovascular death risk similar to the one 
observed in the HFrEF group. Further interventional and prospective studies are needed to confirm and, 
possibly, to translate our results into the daily HFmrEF clinical management.  
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Figure 1. Clinical, therapeutic and functional characteristics of the rec-HFmrEF and HFrEF groups 
Differences in clinical profile (age, gender, fibrillation and ischemic heart disease) (Panel A), treatment with 
disease modifier drugs (ACEi/ARB, beta-blockers and MRA) (Panel B) and cardiopulmonary exercise test 
parameters (pVO2 , peak heart rate, ventilatory efficiency and peak woarkload) (Panel C) between rec-
HFmrEF and HFrEF patients. See table 1 for further details. 
rec-HFmrEF, heart failure with recovered mid-range left ventricular ejection fraction; HFrEF, heart failure 
with reduced left ventricular ejection fraction; ACEi, angiotensin converting enzyme inhibitors; ARB, 
angiotensin receptor blockers; MRA, mineralocorticoid receptor antagonists; peak VO2, peak oxygen 
uptake; VE/VCO2 slope, ventilatory efficiency; peak HR, heart rate;  
***, p-value <0.001; **, p-value <0.01; *, p-value < 0.05. 
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Figure 2. Cardiovascular mortality according to left ventricular ejection fraction categories. 
Kaplan–Meier estimator of CV mortality at 5 years conditional on significant independent variables 
according to left ventricular ejection fraction in the overall study sample (Panel A) and age, gender, BMI, 
MDRD, NYHA class, Hb, Na and pVO2 (% of predicted) and disease modifier drugs (angiotensin converting 
enzyme inhibitors /angiotensin receptor antagonists, β-blockers and mineralocorticoid receptor 
antagonists) (Panel B). 
rec-HFmrEF, heart failure with recovered mid-range left ventricular ejection fraction; HFrEF, heart failure 
with reduced left ventricular ejection fraction; CV, cardiovascular. 
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Figure 3. Cardiovascular mortality in the rec-HFmrEF sample according to CPET parameters. 
Receiver-operating curves (ROC) and Kaplan–Meier estimator of CV mortality at 5 years in the rec-HFmrEF 
sample for peak oxygen uptake (peak VO2 ≤55%) (Panel A), for ventilatory efficiency (VE/VCO2 slope ≥31) 
(Panel B) and and Kaplan–Meier estimator of CV mortality at 5 years in the rec-HFmrEF sample for both cut-
off values (Panel C). See Table 4 for the accuracy data. rec-HFmrEF, heart failure with recovered mid-range 
left ventricular ejection fraction; CPET, cardiopulmonary exercise test; CV, cardiovascular. 
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Figure 4. Incidence rate of cardiovascular mortality in different HF subgroups.  
Incidence rate of CV mortality at 5 years in the overall HFrEF and rec-HFmrEF samples and in rec-HFmrEF 
subgroups categorized according to the best cut-off values of peak VO2 and VE/VCO2 slope.    
HFrEF, heart failure with reduced left ventricular ejection fraction; rec-HFmrEF, heart failure with recovered 
mid-range left ventricular ejection fraction; CV, cardiovascular.  
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